Mitoconix Bio
Therapeutics for Neurodegenerative Diseases
Company Overview
Snapshot
Founded in June 2016 by Daria Mochly-Rosen, Mitoconix Bio operates with 1–10 employees. The company has secured funding across two rounds from six investors. In June 2017, Mitoconix Bio raised an A Round.
Business overview
Mitoconix Bio is a Health Tech & Life Sciences company focused on developing disease-modifying therapeutics for neurodegenerative diseases. The company's core technology involves an inhibitor designed to improve mitochondrial health by targeting pathological mitochondrial fragmentation and dysfunction. This drug has demonstrated efficacy in animal models of Huntington's and Parkinson's diseases, and beneficial activity in patient-derived cells for Huntington's, sporadic and genetic Parkinson's, and sporadic and genetic Alzheimer's diseases. Mitoconix Bio operates within the Pharmaceuticals sector, specifically in Drugs Discovery & Development, serving the Healthcare & Life Sciences market.
Strategic signal
In July 2019, Mitoconix Bio ceased to operate. This indicates a significant and negative operational shift for the company, signaling to investors and innovation teams that the venture is no longer active in the market.
Log in to access full profile ›Company Intelligence Q&A
- What is Mitoconix Bio's primary focus?
- Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases, including Huntington's, Parkinson's, and Alzheimer's.
- When was Mitoconix Bio founded?
- Mitoconix Bio was founded in June 2016.
- What was a key funding event for Mitoconix Bio?
- In June 2017, Mitoconix Bio completed an A Round of funding with participation from investors including.
- What is the status of Mitoconix Bio?
- Mitoconix Bio ceased to operate in July 2019.
- Which investor participated in Mitoconix Bio's August 2016 funding round?
- In August 2016, FutuRx participated in a funding round for Mitoconix Bio.